In This Article:
Charles T. Todd, Jr. named CEO and Chair of the Board
MIAMI, FLORIDA / ACCESS Newswire / April 23, 2025 / Ludwig Enterprises, Inc. (the "Company"), has appointed Charles T. Todd, Jr. as Chief Executive Officer and Chairman of the Board of Directors, to oversee the Company's transition from an innovative research and diagnostic development business to a healthcare solutions provider. Mr. Todd has over 40 years of experience in the Clinical Laboratory Industry in addition to overseeing the growth and development of other innovative healthcare companies.
Mr. Todd founded the first cancer specialty laboratory in the United States which was subsequently acquired by BioReference Laboratories, Inc. ("BioReference") where he was ultimately promoted to Executive Vice President. Mr. Todd was responsible for all sales, marketing, laboratory acquisitions and payor contracts. During his 20 year tenure with BioReference, Mr. Todd led their growth from a northeast regional laboratory to the third largest clinical laboratory in the United States. BioReference was sold to OPKO Health, Inc. for $1.2 Billion Dollars in 2015. Mr. Todd left BioReference two years after the sale and since leaving Mr. Todd has helped other medical device companies establish new markets and develop operational excellence. As CEO and Chair of the Board of Directors, Mr. Todd brings a unique vision to architect and execute the transition of the company.
The Company is excited to bring him aboard and leverage his vast experience commercializing new products and services in the clinical laboratory and cancer diagnostics industry.
Marvin S. Hausman, MD, Co-Founder and Chief Science Officer of the Company, articulated: "Mr. Todd has exceptional knowledge, insight, and experience in clinical diagnostic laboratory operations. His strategic plans for our growth will be as rewarding to our shareholders as it will be to the patient community as we roll out our cancer diagnostic program, especially our noninvasive cheek cell breast cancer test.
We are transforming the Cancer Screening Market. Our patent-pending technology uses 48 mRNA markers, nanoscale detection, and artificial intelligence (AI) to provide a non-invasive, painless, convenient, and highly accurate multi-cancer early detection screening via a simple Cheek Swab. This innovative approach gives us a strong competitive edge.
Mr. Todd stated: "I am honored and humbled to accept the positions of Chief Executive Officer and Chairman of the Company. There is enormous potential here, and I relish the challenges ahead. I have had a long and successful career, and this opportunity will be the crown jewel of my professional life."